Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have BRCA1/2 Mutations

Trial Identifier: D081LC00002
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co, Inc.
Foundation Medicine, Inc.
Myriad Genetics, Inc.
Start Date: July 2022
Primary Completion Date: October 2024
Study Completion Date: July 2025
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100050
CN Bengbu, CN, 233004
CN Changsha, CN, 410013
CN Changsha, CN, 410008
CN Chengdu, CN, 610000
CN Chongqing, CN, 408099
CN fuzhou, CN, 350005
CN Guangzhou, CN, 510060
CN Guangzhou, CN, 510180
CN Hangzhou, CN, 310014
CN Hangzhou, CN, 310003
CN Hangzhou, CN, 310009
CN Hefei, CN, 230601
CN Jiaxing, CN, 314001
CN Jinan, CN, 250012
CN Jinan, CN, 250021
CN Jining, CN, 272029
CN Kunming, CN, 650101
CN Lanzhou, CN, 730030
CN Linyi, CN, 276000
CN Nanchang, CN, 330006
CN Nantong, CN, 226361
CN Ningbo, CN, 315010
CN Shanghai, CN, 200002
CN Shanghai, CN, 200032
CN Shenyang, CN, 110004
CN Suzhou, CN, 215004
CN Taiyuan, CN, 030000
CN Tianjin, CN, 300060
CN Wanzhou, CN, 404000
CN Wuhan, CN, 430022
CN Wuxi, CN, 214023
CN Wuxi, CN, 214002
CN Xi 'an, CN, 710077
CN Zhengzhou, CN, 450052